These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 37906445)

  • 41. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
    Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
    Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
    Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New developments in allotransplant immunology.
    Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
    Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.
    Chandar R; Meena S; Varla H; Ramakrishnan B; Vellaichamy Swaminathan V; Uppuluri R; Raj R
    Pediatr Transplant; 2022 Aug; 26(5):e14293. PubMed ID: 35437875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.
    Fricke S; Hilger N; Fricke C; Schönfelder U; Behre G; Ruschpler P; Boldt A; Oelkrug C; Sack U; Emmrich F
    Cell Mol Life Sci; 2014 Jun; 71(11):2135-48. PubMed ID: 24067988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
    Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
    Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies.
    Saliba RM; Srour SA; Greenbaum U; Ma Q; Carmazzi Y; Moller M; Wood J; Ciurea SO; Kongtim P; Rondon G; Li D; Saengboon S; Alousi AM; Rezvani K; Shpall EJ; Cao K; Champlin RE; Zou J
    Front Immunol; 2022; 13():904718. PubMed ID: 35874659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.
    Chung YJ; Fry TJ; Aplan PD
    PLoS One; 2017; 12(9):e0185219. PubMed ID: 28953912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
    Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
    Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.
    Kim S; Santhanam S; Lim S; Choi J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases.
    Umeda K; Imai K; Yanagimachi M; Yabe H; Kobayashi M; Takahashi Y; Kajiwara M; Yoshida N; Cho Y; Inoue M; Hashii Y; Atsuta Y; Morio T;
    Int J Hematol; 2020 Jun; 111(6):869-876. PubMed ID: 32052319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.